SAT0426 Serum uric acid levels predict damage accrual in systemic lupus erythematosus patients
Authors: C. Elera-Fitzcarrald, C. Reategui-Sokolova, R.V. Gamboa-Cárdenas, M. Medina, F. Zevallos, V. Pimentel-Quiroz, J.M. Cucho-Venegas, J.L. Alfaro-Lozano, Z.J. Rodríguez-Bellido, C.A. Pastor-Asurza, R.A. Perich-Campos, G. Alarcón, M.F. Ugarte-Gil
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Serum uric acid levels have been reported as predictors of cardiovascular and renal morbidity(,<sup>1</sup> and, of increasing the risk of renal damage in systemic lupus erythematosus (SLE) patients(.<sup>2</sup> However, their role as predictors of global damage accrual in SLE patients has not been determined. <h3>Objectives</h3> To determine whether uric acid levels predict new damage in SLE patients. <h3>Methods</h3> This is a longitudinal study of SLE patients from a single centre cohort which started in 2012. Visits were performed every six months. Patients with at least two visits were included. Demographic and clinical characteristics as well as treatment were recorded at every visit. Disease activity was ascertained with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and damage with the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) damage index (SDI). Prednisone use was recorded as current daily dose and time of exposure. Immunosuppressive drugs and antimalarial use was recorded as current, past or never. All variables were ascertained at baseline, with the exception of new damage which was assessed at the subsequent visits. Univariable and multivariable Cox-regression models were performed to determine the impact of uric acid levels on the risk of new damage. Multivariable models were adjusted for age at diagnosis, disease duration, socioeconomic status, SLEDAI, SDI, comorbidities and use of prednisone, immunosuppressive drugs and antimalarials. <h3>Results</h3> Two hundred and thirty-seven patients were evaluated. The mean (SD) age at diagnosis was 35.9 (13.1) years, 220 patients (92.8%) were female, nearly all were Mestizo, disease duration was 7.3 (6.6) years. The mean SLEDAI and SDI were 5.1 (4.2) and 0.9 (1.3), respectively. The Charlson comorbidity index was 0.5 (0.9). Uric acid levels were 4.5 (1.4) mg/dl. The mean current prednisone dose 7.1 (6.4) mg/d. The duration of exposure to prednisone was 6.9 (6.2) years. Follow-up time was 3.1 (1.3) years. One hundred and twelve (47.3%) patients accrued damage during the follow-up. In univariable and multivariable analyses, uric acid levels predicted new damage [HR=1.14 (95% CI 1.01–1.28); p=0.026 and HR=1-.16 (95% CI 1.00–1.34); p=0.043, respectively]. <h3>Conclusions</h3> Higher uric acid levels predicted the development of new damage in our SLE patients. <h3>References</h3> [1] Zoccali C, et al. Uric acid, hypertension, and cardiovascular and renal complications. Current hypertension reports. 2013;15(6):531–7. [2] Reategui-Sokolova C, et al. Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients. Clinical rheumatology2017;36(4):845–52. <h3>Disclosure of Interest</h3> None declared